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ABSTRACT 
 
BACKGROUND: Several plasma lipid and non-lipid biomarkers have been shown to 
predict major cardiovascular events in population studies, but data on novel biomarkers in 
secondary prevention are sparse and there exists marked heterogeneity across trials. 
OBJECTIVE: Aim of our study was to determine whether temporary changes of traditional 
lipid and new lipid and non-lipid biomarkers like UACR, hs-CRP, Nt-proBNP, Lp(a), ApoA 
and ApoB, observed during a Secondary Prevention and Cardiac Rehabilitation Program 
(SPCRP), are associated to CV risk (primary combined end-point of cardiovascular 
mortality and re-hospitalization). MATERIALS AND METHODS: we enrolled 167 ACS 
patients, 137 males (82%) and 30 females (18%); mean age of participants was 59.8 ± 11 
years (32.5-78.5). The 12-months SPCRP was based on nurse counselling, 
multispecialistic visits and controlled training. Serial blood samples (plasma levels of TC, 
HDL C, LDL C, TG, Apo A, Apo B, hs-CRP, Nt-proBNP, Lp(a), UACR), BMI and WHR 
were assessed at baseline, at 6 and 12 months. A telephonic follow up [median of 36.2 
months (27.7 – 77.0)] was performed to collect data. CONCLUSIONS: Among all the 
cardiac biomarkers considered only HDL C, Apo A and Nt-proBNP resulted to be 
independent predictors of cardiovascular mortality and re-hospitalization. Prognostic value 
of novel biomarkers in secondary cardiovascular prevention needs further investigations.   
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ABBREVIATIONS 
 
ACS Acute Coronary Syndrome 
Apo A  Apolipoprotein A 
Apo B Apolipoprotein B 
CAD coronary artery disease 
CHD coronary heart disease  
CI Confidence interval 
CRP C-reactive protein  
CV cardiovascular  
CVD cardiovascular disease 
HDL C  High-density lipoprotein cholesterol   
HF Heart Failure  
Hs-CRP high-sensitivity C-reactive protein  
LDL C Low-density lipoprotein cholesterol     
LVEF Left Ventricular Ejection Fraction  
Lp(a)  Lipoprotein(a)  
NP: Natriuretic Peptides  
Nt-proBNP N-terminal pro-brain natriuretic peptide 
SPCRP Secondary Prevention and Cardiac Rehabilitation Program 
TC Total cholesterol  
TG  Triglycerides 
UACR Urinary Albumin/Creatinine Ratio 
6m six months 
12m twelve months 
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INTRODUCTION     
 
New cardiovascular (CV) risk markers like high sensitivity C-reactive protein (hs-CRP),1,2 
brain natriuretic peptide (BNP),3 N-terminal pro brain natriuretic peptide (Nt-proBNP) 4 and 
urine albumin/creatinine ratio (UACR)5 have been demonstrated to predict CV events in 
the general population. Although they add significantly to traditional CV risk factors their 
role in risk stratification and identification of subjects for primary prevention is not yet 
clear.6 It has been previously shown that hs-CRP, Nt-proBNP and UACR provide additive 
prognostic information in the general population6 as well as in hypertensive patients7 
probably because they are markers of damage in different parts of the CV system 
occurring at different time points in the atherosclerotic process.6 High hs-CRP is thought to 
reflect the early atherosclerotic process,8 high Nt-proBNP is thought to reflect the 
haemodynamic load on the heart and thereby CV hypertrophy and left ventricular 
dysfunction,9 and high UACR is thought to reflect endothelial dysfunction and 
microvascular damage.10 Therefore, it is likely that the predictive values of these three risk 
markers will differentiate depending on presence or absence of subclinical and overt CV 
disease. It is generally accepted that primary prevention is indicated in subjects with an 
estimated 10-year risk of CV death of 5% or above as estimated by HeartScore.11,12 
However, it is less clear whether primary prevention is appropriate in subjects with a 
HeartScore below 5%, but with high CV risk indicated by new risk markers.  
Olsen et al in 2009 tried to investigate the predictive values of hs-CRP, Nt-proBNP and 
UACR on the composite CV end point of CV death, non-fatal myocardial infarction and 
non-fatal stroke in different CV risk groups based on HeartScore and history of CV disease 
or diabetes; they also tried to determine whether hs-CRP, Nt-proBNP and UACR added to 
risk prediction based on HeartScore and history of diabetes or CV disease by actually 
were able to change the original risk classification. Their data suggested that hs-CRP 
5 
 
should be used in subjects with low-moderate CV risk based on Heart-Score, Nt-proBNP 
in subjects with high CV risk, known CV disease or diabetes and UACR in all subjects.13 
Data regarding an association between Lipoprotein (a) (Lp(a)) and CV risk in secondary 
prevention populations are sparse. 14 
Both epidemiological and experimental studies confirm the protective effect of high-density 
lipoprotein cholesterol (HDL C) on the onset of CAD (coronary artery disease) despite LDL 
C level, owing to the reverse cholesterol transport process of HDL C.15-18  
However, in recent decades, some researchers assert that other newer lipid 
measurements, including non-HDL C, Apolipoprotein (Apo) A-I, apo B, and lipid ratios, are 
superior to traditional LDL C in predicting adverse outcomes in general population. Some 
researchers even suggest that apo B can replace the standard “lipid profile” as a target for 
monitoring and therapy in at-risk patients.19-21 Besides, several translational studies find 
that the endothelial effect of HDL C may be totally different in patients with various clinical 
conditions.22-24 Thus, the association between various lipid measurements and secondary 
risk of CAD deserves more attention due to limited and inconsistent results of previous 
studies.25 
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OBJECTIVE  
Aim of our study was to determine whether temporary changes of traditional lipid and  
new both lipid and non-lipid biomarkers like UACR, hs-CRP, Nt-proBNP, Lp(a), ApoA and 
ApoB, assessed during a Secondary Prevention and Cardiac Rehabilitation Program 
(SPCRP), are associated to CV risk (primary combined end-point of cardiovascular 
mortality and re-hospitalization). We also evaluated global effectiveness of the 12-months 
SPCRP, consisting in a first intensive therapeutic phase (first 6 months with strict follow-
up, counseling, drug titration and controlled physical activity) and in a second self-
managed phase.   
 
 
MATERIAL AND METHODS 
From April 2008 to March 2009 we enrolled 167 consecutive ACS (Acute Coronary 
Syndrome) patients, 18% F, 82% M in a SPCRP. The 12-months SPCRP was based on 
nurse counselling, multispecialistic visits and controlled training. Serial blood samples 
(plasma levels of TC, HDL C, LDL C, TG, Apo A, Apo B, hs-CRP, Nt-proBNP, Lp(a), 
UACR and biometric parameters such as BMI (Body Mass Index) and WHR (Waist-to-hip 
ratio) were assessed at discharge (baseline), at 6 and 12 months. A telephonic follow up 
[median of 36.2 months (27.7 – 77.0)] was performed to collect data.  
Statistical analysis  
Continuous variables not deviating from a Gaussian distribution are reported as mean and 
standard deviation along with 95% confidence intervals, while variables with skewed 
distribution are reported as median (interquartile range). Comparisons were performed 
using the Student t test for paired data and Wilcoxon signed-rank test for continuous 
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variables as appropriate. Changes in biomarkers were tested with a signed-rank test, and 
compared between treatment groups with a Wilcoxon rank-sum test. The Bonferroni 
correction was used when needed to counteract the problem of multiple comparisons. 
Cox proportional hazards modeling was used to estimate the hazard ratios (HRs) of the 
combined end-point cardiovascular mortality and re-hospitalization; all models were 
adjusted for age and gender. Variables that resulted significant predictors of event-free 
survival were then included in a multivariate model. 
Analyses were performed with STATA software version 10 (Stata Corp – College Station, 
TX, USA). 
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RESULTS  
We enrolled 167 patients, 137 males (82%) and 30 females (18%); mean age of 
participants was 59.8 ± 11 years (32.5-78.5). Discharge diagnosis were: Unstable Angina 
(25%), Non ST-Elevation Myocardial Infarction (31%) and ST-Elevation Myocardial 
Infarction (44%). Traditional CV risk factor were widely present in our population (arterial 
hypertension: 71.2%, family history of CHD:  70%, dyslipidemia: 80.2%, diabetes: 17.9%, 
smoking habit: 37% of patients). 
There was a significant change in WHR during SPCRP (baseline vs 6m (0.98 ± 0.07 [95% 
CI 0.96-0.99] vs 0.96 ± 0.07 [95% CI 0 .95-0.98], t = 2.9537, p = 0.0039) while no 
significant variations were evidenced during the last 6m of the program (WHR 6m vs 12m 
(0.97± 0.07 [95% CI 0.96-0.99] vs 0.96 ± 0.09 [95% CI 0.94-0.98], NS).  
No significant difference were observed for BMI values (kg/m2) neither in the first phase 
(BMI baseline vs 6m (27.66 ± 4.13 [95% CI 27-28] vs 28.25 ± 9.41 [95% CI 26.77-29.73], 
NS) nor in the second one (BMI 6m vs 12m (28.26 ± 9.53 [95% CI 26.75-29.77] vs 27.14 ± 
3.55 [95% CI 26.58-27.71], t = 1.6474, NS).  
The difference between TC values (mg/dl) at baseline and at 6m was statistically 
significant (172.97 ± 37.4 [95% CI 167-179] vs 161.46 ± 34.55 [95% CI 156-167], t = 
3.5721, p=0.0005) while no significant difference was evidenced between TC values at 6m 
and those at 12m (161.40 ± 34.38 [95% CI 156-167] vs 161.42 ± 31.12 [95% CI 157-166], 
NS). 
There was a significant difference between LDL C (mg/dl) at baseline and its values at 6m 
(104.66 ± 34.16 [95% CI 99-110] vs 92.08 ± 28.59 [95% CI  87-97], t = 4.3578, p< 
0.00001) while no significant differences were registered during the last 6m of SPCRP 
(LDL C 6m vs 12m (91.39 ± 28.67 [95% CI 87-96] vs 89.1 ± 24.15 [95% CI  85-93], NS).  
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A significant difference was found between HDL C levels (mg/dl) during the whole SPCRP 
period (HDL C baseline vs 6m (41.01 ± 10.96 [95% CI 39-43] vs 44.61 ± 10.12 [95% CI  
43-46], t = -5.9003, p< 0.00001) and HDL C 6m vs 12m (44.61 ± 10.06 [95% CI 43-46] vs 
46.22 ± 10.54 [95% CI 45-48], t = -3.6408, p=0.0004).  
Even when TG values (mg/dl) during SPCRP were compared, there was a significant 
difference between baseline and 6m (TG baseline vs 6m (134.72 ± 68.77 [95% CI 124-
146] vs 120.64 ± 61.51 [95% CI 110-130], t = 2.727, p = 0.014) but no difference was 
evident between 6m and 12m (130.07 ± 131.49 [95% CI 110-151] vs 127.07 ± 86.34 [95% 
CI 114-141], NS). 
A significant difference was evidenced between Apo A levels (g/L) at baseline and at 6m 
(1.25 ± 0.21 [95% CI 1.20-1.29] vs 1.36 ± 0.23 [95% CI 1.31-1.41], t = -8.2126, p< 
0.00001) and Apo A at 6m and at 12m (1.33 ± 0.21[95% CI 1.29-1.36] vs 1.38 ± 0.22 [95% 
CI 1.34-1.41], t = -4.2103, p<0.00001).  
In contrast, no significant differences were found when Apo B values (g/L) during SPCRP 
were compared (Apo B at baseline vs 6m (0.84 ± 0.21 [95% CI 0.79-0.88] vs 0.81 ± 0.19 
[95% CI  0.77-0.85], NS) and Apo B at 6m vs 12m (0.82 ± 0.22 [95% CI 0.78-0.85 ] vs 0.80 
± 0.19 [95% CI0.77-0.83], NS).  
The median Lp(a) level at baseline was 345.5 (199-933.25) mg/L, at 6m was 262 (199-
674.75) mg/L and at 12m was 206 (199-653) mg/L The difference between Lp(a) values at 
baseline and at 6m was statistically significant (z = 2.200, p =0.028). On the contrary, the  
difference between Lp(a) values at 6m and 12m was not statistically significant.  
The median UACR level (mg/g) at baseline was 6 (4-14), at 6m was 6 (4-13) and at 12m 
was 6 (4-11). The difference between UACR values both at baseline vs 6m and at 6m vs 
12m were not statistically significant.  
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The median NT-proBNP level (ng/L) at baseline was 275 (110-722), at 6m was 103.5 
(43.5-199.25) and at 12m was 105 (42-208). The difference between NT-proBNP values at 
baseline and at 6m was statistically significant (z =6.513, p <0.0001), while the difference 
between NT-pro BNP values at 6m and 12m was not statistically significant (z =0.251,NS).  
The median hs-CRP level at baseline was 2.92 (1.33-6.49) mg/L, at 6m was 1.95 (0.67-
3.8825) mg/L and at 12m was 1.76 (0.81-3.0425) mg/L. The difference between hs-CRP 
values at baseline and at 6m was statistically significant (z =4.151, p =0.000). The  
difference between hs-CRP values at 6m and 12m remained statistically significant (z = 
2.002, p = 0.045). 
During a median follow up of 36.2 months (27.7 – 77.0) 4 patients died and 51 were 
hospitalized for cardiovascular reasons. Figure 1 shows event-free survival over time.  
 
Figure 1. Event-free survival 
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At the Cox analysis, after adjusting for age and gender, both 6m HDL C (HR=0.97; 
p=0.0363) and 6m Apo A (HR=0.1704; p=0.021) were predictors of cardiac death/re-
hospitalization. Six months Nt-proBNP (HR=1.0007, p=0.041) showed a predictive value 
too.  
Other variables such as  baseline LVEF,  6m BMI, 6m WHR, 6m hs-CRP, 6m LDL C, 6m 
TG, 6m Apo B, 6m Lp(a), 6m UACR did not show any significant predictive value. 
In order to include the significant predictors in a multivariate Cox model we had to keep 
into account that TC and HDL C are significantly correlated (p<0.0001) so they cannot be 
included simultaneously in a multivariate model, in order to prevent serious 
multicollinearity problems; the same hold true for HDL C and Apo A (p<0.0001) that were 
thus included in two different models. 
When HDL C, Nt-proBNP and baseline LVEF where included in a multivariate model, 
always adjusting for age and gender, only HDL C proved to be an independent and 
significant predictor of event-free survival (HR=0.9689, p=0.043) (see table 1 below). 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
sesso |   1.126807   .4602625     0.29   0.770     .5060138    2.509207 
         eta |   .9962187   .0143586    -0.26   0.793     .9684702    1.024762 
       hdl_2 |   .9689214   .0151141    -2.02   0.043     .9397466     .999002 
        fe_1 |   .0820049   .1377223    -1.49   0.136       .00305    2.204865 
       bnp_2 |   1.000284   .0003966     0.72   0.473     .9995073    1.001062 
 
Table 1: multivariate analysis  
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Figure 2 depict how HDL C values above median are associated with a higher event-free 
survival. 
 
 
 
 
 
 
 
 
Figure 
2: Event-free survival and HDL 
Replacing HDL C with Apo A in the multivariate Cox model led to the same conclusions: 
Apo A was the only significant independent predictor (HR=0.178, p=0.029) (see table 2 
below). 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
sesso |   1.305779   .5428915     0.64   0.521     .5780612    2.949618 
         eta |   .9916433   .0142184    -0.59   0.558     .9641638    1.019906 
      apoa_2 |   .1781493   .1407685    -2.18   0.029     .0378607    .8382614 
        fe_1 |   .1926441   .3412267    -0.93   0.352     .0059847    6.201149 
       bnp_2 |   1.000396   .0003994     0.99   0.322     .9996131    1.001179 
------------------------------------------------------------------------------ 
Table 2: multivariate analysis 
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 DISCUSSION 
 
There has been much recent interest in the ability of non-lipid biomarkers associated with 
systemic inflammation, oxidative stress, tissue remodelling and/or insulin resistance to 
predict adverse cardiovascular outcomes and to identify individuals at high risk of future 
coronary heart disease (CHD) events and stroke 26,27. 
The concentration of one of these, hs-CRP, predicts future CV events in apparently 
healthy individuals and in subjects treated with statins.28-30     
The results of these studies have been used to support the argument that the 
concentration of non-lipid biomarkers such as hs-CRP should be included in algorithms 
designed to predict CV outcomes and to measure the efficacy of statin treatment. 31 
However, there are inconsistencies, with some studies finding that levels of non-lipid 
biomarkers have minimal predictive power beyond of established CHD risk factors. 32-35  
C-reactive protein (CRP) , among other systemic inflammatory mediators, has been widely 
accepted as a potent risk indicator, independently predicting future CV events. The impact 
of CRP on CV outcome has been corroborated by a large number of observational studies 
and meta-analyses. These studies show that an elevated CRP has a clear prognostic 
value for major CV events and mortality, whereas the lowering of CRP is associated with a 
reduction in CV risk. Combining these findings with experimental observations has lead to 
a paradigm shift in which CRP is no longer merely a marker, but is increasingly considered 
as a mediator of CV disease 36. Our results show a significant reduction of hs-CRP values 
from baseline to 12m (first phase: p =0.000, second phase: p = 0.045), but hs-CRP did not 
show any predictive value. 
Since the widespread availability of hs-CRP, a large number of studies have investigated 
whether CRP is associated with atherosclerosis and vascular disease in animals and large 
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human cohorts to determine whether hs-CRP is a crucial causal mediator or a non-specific 
marker (bystander) of vascular disease. More recently, genetic studies have applied the 
principle of Mendelian randomization to distinguish whether genetic variations in the CRP 
gene are associated with circulating CRP levels and CHD. Furthermore, a recent clinical 
trial posits that lowering hs-CRP is associated with a reduction in CHD outcomes. 37  
With CRP being a strong risk factor for CV disease, and in light of evidence that CRP may 
play a biological role in atherosclerosis, the question arises as to whether an intervention 
to lower CRP levels may constitute a viable therapeutic strategy. In support of this 
hypothesis, several known anti-atherosclerotic interventions have been reported to reduce 
CRP. An example of a lifestyle intervention that reduces CRP levels, as well as CV risk, is 
weight loss. In a randomized, controlled trial consisting of 120 obese women, half the 
participants received detailed advice about how to achieve 10% weight reduction using 
diet and exercise, whereas the other half were given general information regarding a 
healthy lifestyle. After 2 years, women in the intervention group had a stronger decrease in 
BMI (p < 0.001), as well as a stronger reduction in CRP levels (p= 0.008), than women in 
the control group. Similarly, weight loss in morbidly obese patients has been shown to 
induce a significant decrease in CRP and IL-6 concentrations in association with an 
improvement of insulin resistance. In another study, baseline measures of obesity were 
significantly associated with CRP levels and subsequent weight loss was shown to result 
in a proportionate reduction in CRP.37 Our data showed a reduction of both WHR and hs- 
CRP during the first 6 months of the program.  
Statin therapy, besides lowering LDL-C, represents a pharmacological intervention that 
reduces both CRP levels and CV risk. Both weight loss and statin therapy apparently 
result in a reduction in low-grade inflammation, underlying a reduction in CV disease risk. 
The big question is: is this anti-atherogenic effect (partially) mediated by CRP reduction, or 
are the lower CRP levels a mere reflection of the reduction in inflammatory status? To 
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answer this question, the impact of specific inhibitors of CRP should be tested. 37 A first 
clue that specific CRP inhibition may be beneficial came in 2006, when Pepys et al. 
reported that a small-molecule inhibitor of CRP was able to reduce myocardial infarct size 
as well as cardiac dysfunction produced by injection of human CRP in rats. 38 
Olsen et al studied a Danish population sample of 2460 individuals, divided in three 
groups: 472 subjects receiving CV medication or having history of diabetes, prior 
myocardial infarction or stroke, 559 high-risk subjects with a 10-year risk of CV death 
above 5% as estimated by HeartScore, and 1429 low-moderate risk subjects with 
estimated risk below 5%. During the following 9.5 years the composite end point of CV 
death, non-fatal myocardial infarction or stroke occurred in 204 subjects. Composite 
endpoint was predicted in all three groups by UACR (HRs: 2.1, 2.1 and 2.3 per 10-fold 
increase, all p<0.001) or by hs-CRP (HRs: 1.9, 1.9 and 1.7 per 10-fold increase, all 
p<0.05), but not by Nt-proBNP (HRs: 1.1, 2.6 and 3.7 per 10-fold increase, last two 
p<0.001) (p<0.05 for interaction). In the low-moderate risk group, pre-specified gender 
adjusted (men/women) cutoff values of UACR> or =0.73/1.06 mg mmol(-1) or hsCRP> or 
=6.0/7.3 mg l(-1) identified a subgroup of 16% who experienced one-third of the composite 
endpoints. In the patient group, combined absence of high UACR and high Nt-proBNP> or 
=110/164 pg ml(-1) (men/women) identified a subgroup of 52% who experienced only 15% 
of the composite endpoints. Additional use of UACR and hs-CRP in subjects with low-
moderate risk and UACR and Nt-proBNP in subjects with known diabetes or CVD changed 
HeartScore risk classification significantly in 19% of the population. 13  
B-type natriuretic peptide and NT-proBNP are markers of cardiac stress but are not 
cardiac-specific. They have comparable clinical utility, and both help in excluding acute 
Heart Failure (HF). Their use prior to discharge in hospitalized patients aids risk 
stratification. There is increasing evidence for risk stratification in acute Pulmonary 
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Embolism and ACS patients. The lower the value, the lower is the risk. A variety of new 
assays, e.g. mid-regional proANP and proBNP are being developed. So far, these assays 
are equivalent but no better than other testing. 
Natriuretic peptides are related to ACS because myocardial ischaemia releases BNP, and 
the coherent diastolic and systolic abnormalities release Natriuretic Peptides (NP) as well. 
In ACS BNP and NT-proBNP values are powerful prognostic markers. Combination with 
cTn improves risk stratification in NSTEMI. In ACS trials, admission values of BNP .80 
ng/L and NT-proBNP .1170 ng/L for men and .2150 ng/L for women identify high-risk 
patients. N-terminal proB-type natriuretic peptide measurements augment the prognostic 
information of clinical risk scores. Usually, NP did not predict recurrent acute myocardial 
infarction or a benefit from an invasive strategy. Optimal time for risk stratification is 
uncertain but studies suggest synergism between early and subsequent values. In patients 
with STEMI, NPs rise rapidly and values are correlated with infarct size and LV 
dysfunction. Among very old subjects with established CVD, NT-proBNP was the strongest 
risk marker for CV events and CV mortality. When estimating risk in secondary prevention 
in very old age, use of NT-proBNP should be considered. 39 
 In secondary prevention in very old patients, measurement of NT-proBNP markedly 
improves prediction of recurrent CV events and CV mortality. 
 NT-proBNP might be used to select older people at the highest risk for recurrent CV 
events who may benefit most from strict secondary prevention. 40  
Our study showed a predictive value for the 6m Nt-proBNP plasma level (HR=1.0007, 
p=0.041). The difference between NT-proBNP values at baseline and at 6m was the only 
one statistically significant  during SPCRP (p <0.0001). UACR did not demonstrate any 
statistically significant variation during SPCRP, and 6m UACR did not show any predictive 
value at Cox analysis. 
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In concordance with earlier LIFE study publications, Ibsen et al showed that the risk for CV 
end points increased in a stepwise fashion with higher values for UACR in the patients 
with diabetes, a population for which the median baseline value of UACR was 3.05 
mg/mmol (versus 1.28 mg/mmol in the overall population). The risk for the composite end 
point in patients with diabetes was increased by UACR≥1.94 mg/mmol. Their data indicate 
that albuminuria at a lower level than what is usually utilized as a cut point in patients with 
diabetes deﬁnes patients at increased risk of CV morbidity and mortality. UACR did not 
predict risk of myocardial infarction. The reason might be that diabetes in itself is a strong 
predictor for CV morbidity and mortality, partly overriding the inﬂuence of albuminuria as a 
risk factor in the present population with rather low levels of albuminuria. In summary, in 
patients with hypertension, diabetes, and ECG-documented left ventricular hypertrophy, 
increasing levels of baseline albuminuria were related to increased risk for CV morbidity 
and mortality. The risk for CV events was closely related to the in-treatment level of UACR, 
i.e., a reduction in albuminuria translated to a reduction in CV events. Their ﬁndings 
support the concept of monitoring of albuminuria in patients with hypertension and 
diabetes as part of proper disease management. 41 
Zandbergen et al demonstrated that normotensive patients with type 2 diabetes and 
miroalbuminuria run a marked risk for CV complications. The risk depends on the rate of 1- 
year change in urinary albumin excretion. Patients with rapid progression of albuminuria 
were at highest risk, whereas patients with regression of albuminuria had the lowest risk. 
This association persisted after adjustment for classic CV risk factors. Besides reducing 
blood pressure, RAS inhibitors are effective in preserving renal and cardiac function in 
diabetic patients. Moreover, they reduce albuminuria up to 40%, significantly more than 
other classes of antihypertensive drugs. Since albuminuria is strongly associated with CV, 
changes in albuminuria during treatment might reflect changes in CVD risk. A few studies 
recently showed that reduction of albuminuria in hypertensive diabetic patients reduces the 
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risk of subsequent CV events. However, these studies investigated hypertensive patients, 
thereby leaving open the possibility that blood pressure lowering explains the CV risk 
reduction, with albuminuria change just an innocent bystander. Sustained reduction in 
albuminuria reflected CV risk reduction in type 2 diabetic patients without hypertension. 
Hence, albuminuria change during treatment seems to reveal therapeutic responsiveness 
independent of blood pressure changes and is therefore useful as a modifiable treatment 
goal. These observations advocate a more aggressive approach to treating albuminuria in 
addition to more aggressive cardioprotective treatment in normotensive diabetic patients 
with elevated levels of albuminuria. 42 
Both sexes face increased risk of all-cause mortality, CV mortality, and end stage renal 
disease with lower estimated glomerular filtration rates and higher albuminuria. These 
findings were robust across a large global consortium. In a pooled analysis of over two 
million participants, Nitsch et al evidenced an increased risk of all-cause and CV mortality 
and end stage renal disease with lower estimated glomerular filtration rate and higher 
albuminuria in both sexes. In stark contrast to previous assertions that kidney disease 
should be defined by a lower threshold for estimated glomerular filtration rate and higher 
threshold for urinary albumin-creatinine ratio in women, they found the association 
between chronic kidney disease and mortality risk to be as strong in women as in men. 
Low estimated glomerular filtration rate or albuminuria should be considered at least as 
potent a risk factor in women as it is in men.43  
Arsenault et al recently suggest that on top of traditional lipid parameters, several 
emerging cardiovascular disease risk factors such as NT-pro-BNP, Lp(a), neopterin, and 
sRAGE (soluble receptor for advanced glycation end products ) are indeed associated with 
the risk of CV events. Whether or not therapies aiming at reducing the plasma levels of 
these biomarkers could be beneficial in terms of CV risk reduction warrants further 
investigation.35 
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Lipoprotein(a) is a genetic, causal risk factor for CVD. Population-based studies have 
determined that there is a continuous, graded association between Lp(a) levels and CV 
risk that is somewhat less marked compared with the association of elevated LDL-C and 
such risk. Partly because both Lp(a) and LDL-C contain the atherogenic moiety apo B100, 
there is a multiplier effect such that CV risk is synergistically increased when both 
lipoproteins are elevated; conversely, elevated Lp(a) becomes more clinically innocuous 
when accompanied by lower levels of LDL-C (<70 mg/dL after maximum statins). Elevated 
LDL-C (or apo B) should always be targeted for lipid-modifying therapy before treating 
elevated Lp(a). Niacin reduces Lp(a) by up to 40% and has been identiﬁed by consensus 
treatment panels as the only medication that consistently lowers Lp(a). Because niacin 
treatment can reduce the apo B100 component of both LDL and Lp(a), such therapy is a 
rational alternative in the presence of refractorily elevated LDL-C despite maximum-dose 
statins or statin combination therapy. Further clinical trials are needed to determine if 
reductions in CV risk can be speciﬁcally ascribed to on-treatment changes in Lp(a). 44  
With respect to its proatherosclerotic and prothrombotic eﬀects, Lp(a) is believed to be a 
promising and critical biomarker for CV risk estimation. Causal relationship between Lp(a) 
and CVD has been recognized and demonstrated in the past decades. In patients with 
established CVD and with target LDL-C level achievement, Lp(a) measurement may add 
addictive value for CV risk stratiﬁcation.45 In our study we  evidenced a significant variation 
in Lpa concentration only during the first phase of  SPCRP (p =0.028). No predictive value 
was registered for 6m Lp(a) concentrations.  
The clinical interest in Lp(a) is largely derived from its role as a CV risk factor. Although not 
considered an established risk factor, Lp(a) levels have been associated with CVD in 
numerous studies. Recently Lp(a) serum levels were found to be associated with the 
severity of aortic atherosclerosis, especially in abdominal aorta, as well as coronary 
atherosclerosis. Moreover a study by Momiyama et al. demonstrated that elevated Lp(a) 
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has incremental prognostic value in symptomatic patients with coronary artery 
revascularization. Lp(a) is involved in the development of atherothrombosis and activation 
of acute inflammation exerting a proatherogenic and hypofibrinolytic eﬀect. Lp(a) plays a 
critical role in the proinflammatory reaction and can be considered as a common joint 
among diﬀerent metabolic systems. Other actions of Lp(a) can be resumed as follows: 
inhibition of the activation of plasminogen; inhibition of the activation of TGF-𝛽𝛽; activation 
of acute inflammation; induction of the expression of adhesion molecules; elevation of the 
production of cytokines. Moreover Lp(a) is implicated in the activation of endothelial 
uptake, oxidative modification, and foam cell formation, suggesting that these processes 
could play an important role in atherosclerosis. Recent findings suggest that Lp(a)-
lowering therapy might be beneficial, at least in some subgroups of patients with high 
Lp(a) levels. A possible future therapeutic approach could include apheresis in high risk 
patients with already maximally reduced LDL cholesterol levels in order to reduce major 
coronary events. However, further studies are needed to define such subgroups with 
regard to Lp(a) levels, apo(a) size, and the presence of other risk factors. 46  
Lp(a) is significantly associated with the risk of CV events in patients with established 
CAD; however, there exists marked heterogeneity across trials. In particular, the 
prognostic value of Lp(a) in patients with low cholesterol levels remains unclear. 
In summary, although it was demonstrated that patients with established CAD who have a 
high level of Lp(a) are at an increased risk of subsequent MACE, the marked 
heterogeneity between studies raises questions regarding the value of Lp(a) as a clinically 
useful biomarker for risk assessment, particularly among patients with well controlled LDL 
cholesterol. Moreover, although Lp(a) may directly contribute to CHD, there is currently 
insufficient evidence to suggest that Lp(a) levels above a discrete cut point should be used 
to guide therapy or that treatment will translate into improved clinical outcomes . Trials are 
now ongoing with novel therapies that reduce Lp(a), such as the novel CETP inhibitors 
21 
 
anacetrapib, mipomersen and PCSK9 inhibitors; although, such therapies influence other 
lipid components in tandem. Recently, a specific antisense oligonucleotide directed toward 
apo(a) was shown to lower apo(a) and Lp(a) levels in transgenic mice, and a phase I trial 
is underway. If a strategy of Lp(a) reduction should ultimately prove to be successful, it will 
be of interest to determine whether benefit is observed regardless of baseline Lp(a) 
concentration or specific reduction in Lp(a).14 
Apo B and apo A-I are important markers of atherogenicity and atheroprotection, 
respectively. On the whole, data in healthy populations and in patients with speciﬁc lipid 
abnormalities and/or preexisting CVD support the concept that apo B is a better measure 
of CVD risk than LDL C. Apo B may be particularly relevant in the setting of insulin 
resistant states, such as diabetes and metabolic syndrome, as patients with these 
disorders often manifest normal LDL C values, but have a preponderance of small, dense 
LDL particles and higher Apo B. Incorporating Apo B and the apo B/apo A-I ratio into risk 
assessment could therefore provide additional and important information on CVD risk. A 
recent Consensus Conference Report 47 recommended that Apo B be added to risk 
assessment in persons at high cardiometabolic risk, with target levels of<90 mg/dL and<80 
mg/dL in high risk and highest risk persons, respectively. Achieving this Apo B goal will 
likely require intensive statin therapy, which has been shown to have beneﬁcial effects on 
all apolipoproteins. Since Apo B is not yet routinely measured in clinical practice, however, 
and since Apo B is the primary Apoprotein component of LDL C, it is prudent at this time to 
continue to lower LDL C levels aggressively using appropriate statin therapy. Although it 
provides superior risk discrimination, the apo B/apo A-I ratio cannot yet be recommended 
for routine clinical use, as clinical trial data showing the beneﬁt on outcomes of increasing 
apo A-I and HDL-C are lacking.48 Our data did not show any significant Apo B variations 
during SPCRP while significant differences were evidenced for both Apo A and HDL C 
during the whole SPCRP. At the Cox analysis, after adjusting for age and gender, both 6m 
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HDL C (HR=0.97; p=0.0363) and 6m Apo A (HR=0.1704; p=0.021) were predictors of 
cardiac death/re-hospitalization. Six months LDL C and 6m Apo B did not show any 
significant predictive value. 
Among Chinese CAD patients, both too low and too high levels of HDL-C may increase all-
cause and CVD mortality. LDL-C remains as an eﬀective and proper predictor for CAD 
prognosis, while LDL/HDL ratio can strengthen the prediction. Besides, high levels of 
apoB, apoB/apoA-Iratio, and low apo A-I level can increase the risk of CVD mortality 
among CAD patients.25 
Fraley et al showed, in a population of patients with ACS, changes in Oxidized LDL 
biomarkers in response to statin therapy in large and speciﬁc subgroups of patients that 
have not been documented previously and provide insights into the interrelationships of 
these biomarkers to clinical, demographic, and inﬂammatory variables. The consistent 
increase in Oxidized Phospholipids/apoB, and to a lesser extent Lp(a), in response to 
atorvastatin across all subgroups tested suggests that it may serve as a benchmark for 
future studies evaluating such biomarkers. Future studies are warranted to assess whether 
changes in these biomarkers reﬂect therapeutic efﬁcacy and predict clinical events. 49  
Nordestgaard et al recommend screening for elevated Lp(a) in those at intermediate or 
high CVD/CHD risk, a desirable level, 50 mg/dL as a function of global cardiovascular risk, 
and use of niacin for Lp(a) and CVD/CHD risk reduction.50     
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CONCLUSIONS 
Our study confirms effectiveness of a 12-months SPCRP in controlling traditional 
cardiovascular risk factors. Among all the cardiac biomarkers considered only HDL C, Apo 
a and Nt-proBNP resulted to be independent predictors of cardiovascular mortality and re-
hospitalization. Other biomarkers did not show any predictive value in our study.  These 
findings suggest that further and larger studies are needed to assess their usefulness in 
secondary prevention. Perhaps, our search for better markers of risk in ACS should move 
away from inﬂammatory markers alone and include biomarkers that reﬂect different, 
unrelated, pathogenic pathways leading to the development and recurrence of the 
condition. Hopes are now placed on genetic markers, transcriptomics, proteomics, and 
metabolomics, which are expected to represent tools that may help us overcome the 
limitations we face at present. However, the challenge for these new markers will be to 
provide true, sizeable, incremental information over and above that provided by existing 
clinical markers of risk and help clinicians to improve patient management.51  
Predictive value of novel biomarkers in secondary cardiovascular prevention needs further 
investigations.   
Additional systematic assessments in large epidemiological cohorts of novel biomarkers 
ideally performed as head-to-head comparisons of data or if not then using patient-level 
meta-analysis will be required to determine the best CVD screening strategies. 51 
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